Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
- Launching into this growth market1 as part of the company’s geographic expansion strategy
-
Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals
Nuceiva® is approved by the
"Launching Evolus in
"As the beauty and healthcare landscape continues to evolve, we understand the importance of working closely with our customers and partners to navigate these changes successfully," said
"Beauty in
The safety and efficacy of Nuceiva® has been evaluated through the company’s TRANSPARENCY clinical program – three Phase III trials3,4 including the largest head-to-head aesthetic pivotal study versus Botox® (onabotulinumtoxinA) to date, and two long-term safety studies5,6. Side effects were similar to others in this class of medicine. For the full list of adverse events, warnings and contraindications consult the Nuceiva® Prescribing Information.
About
Forward Looking Statements
This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements that relate to the status of regulatory processes, future plans, events, prospects or performance and statements containing the words “plans,” “expects,” “believes,” “strategy,” “opportunity,” “anticipates,” “outlook,” “designed,” or other forms of these words or similar expressions, although not all forward-looking statements contain these identifying words. The company’s forward-looking statements include, but are not limited to, statements related to the company’s prospects, geographical expansion, milestones and programs.
Forward-looking statements involve risks and uncertainties that could cause actual results or experiences to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with our ability to address all of our losses, costs, expenses, liabilities and damages resulting from the settlement agreement with Daewoong and our ability to comply with the terms and conditions in the Allergan/Medytox Settlement Agreements, the continued impact of COVID-19 on our business and the economy generally, uncertainties related to customer and consumer adoption of Nuceiva® / Jeuveau®, the efficiency and operability of our digital platform or commercialization strategies, competition and market dynamics, and our ability to maintain regulatory approval of Nuceiva® / Jeuveau® and other risks described in Evolus’ filings with the
Jeuveau® and Nuceiva® are registered trademarks of
Evolysse™ is a trademark of
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Botox® (Botulinum toxin type A) is a registered trademark of
References:
-
Decision Research Group (DRG) Aesthetic Injectables Market Insights,Europe ,July 2023 . Data on file - https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-PI-01255-1&d=20240723172310101 (Accessed 23/07/24)
-
Berthold-Josef Rzany , MD, ScM et al.Aesthetic Surgery Journal , 2019, 1–16 -
Kenneth R. Beer et al. Dermatol Surgery 2019; 45 (11); 1381 – 1393 -
Joely Kaufman-Janette , MD et al.Aesthetic Surgery Journal 2021, 1–14 -
Z. Paul Lorenc , MD, FACS et al.Aesthetic Surgery Journal 2021, 1–16
* Measured by comparing year-over-year revenue growth of each aesthetic neurotoxin on the market for the entirety of each comparable year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730657453/en/
Investor Contact:
Vice President, Head of Global Investor Relations and Corporate Communications
Tel: +1-(248) 202-9267
Email: ir@evolus.com
Media Contacts:
Email: Media@Evolus.com
Communications Consultant,
Tel: +447738506476
Email: janet.kettels@evolus.com
Source: